Restructuring (Tables)

6 Months Ended

Jun. 28, 2026

Restructuring and Related Activities [Abstract]

The following table summarizes the restructuring expenses for 2026 and 2025:


(Pre-tax Dollars in Millions)	Q2 2026	Q2 2025	Q2 YTD 2026	Q2 YTD 2025
Innovative Medicine supply chain(1)	$200	—	200	—
MedTech Segment Surgery franchise(2)	59	29	114	29
MedTech Segment Orthopaedics franchise(3)	17	50	24	105

Total Programs	$276	79	338	134

(1)Included $18 million in Cost of products sold and $182 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal second quarter and fiscal six months of 2026.

(2)Included $31 million in Restructuring, $4 million in Cost of products sold and $24 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal second quarter of 2026. Included $61 million in Restructuring, $24 million in Cost of products sold and $29 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal six months of 2026. Included $29 million in Restructuring on the Consolidated Statement of Earnings in the fiscal second quarter and fiscal six months of 2025.

(3)Included $3 million in Restructuring, $13 million in Cost of products sold and $1 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal second quarter of 2026. Included $5 million in Restructuring, $18 million in Cost of products sold and $1 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal six months of 2026. Included $35 million in Restructuring and $15 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal second quarter of 2025. Included $52 million in Restructuring, $23 million in Cost of products sold and $30 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal six months of 2025.